With a microfluidics platform designed for cell biology, the founders of Incept BioSystems realized that they had the opportunity to improve the quality of embryos destined for in vitro fertilization. IVF represents a great first market for a small medtech company; and larger markets in cell therapy loom ahead for Incept.
PO Box 4425
Ann Arbor, MI 48103
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Multi-blockbuster falls short in a giant cell arteritis study.
Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.
4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.
The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.
